IGHV3-30-2: A Potential Drug Target Or Biomarker (G28438)

Target Name: IGHV3-30-2

NCBI ID: G28438

IGHV3-30-2

Other Name(s): IGHV3302 | 3-30.2P | immunoglobulin heavy variable 3-30-2 (pseudogene) | Immunoglobulin heavy variable 3-30-2 (pseudogene)

IGHV3-30-2: A Potential Drug Target Or Biomarker

IGHV3-30-2 (IGHV3302) is a protein that is expressed in the human erythrocytes, which are the red blood cells responsible for carrying oxygen throughout the body. IGHV3-30-2 is a member of the Interleukin-G receptor family, which is a well-known signaling pathway that is involved in the regulation of inflammation, immune response, and hematopoiesis.

IGHV3-30-2 has been identified as a potential drug target or biomarker for a variety of diseases, including cardiovascular disease, autoimmune disorders, and cancer. One of the main reasons for its potential as a drug target is its involvement in the regulation of inflammation and immune response.

Studies have shown that IGHV3-30-2 is involved in the regulation of inflammation response, both in the context of systemic inflammation and in the regulation of immune cells. IGHV3-30-2 has been shown to play a role in the regulation of the production and function of natural killer cells, which are a crucial part of the immune system and are responsible for targeting and destroying infected or abnormal cells in the body.

In addition to its role in immune regulation, IGHV3-30-2 has also been shown to be involved in the regulation of inflammation in the context of autoimmune disorders. These disorders involve the misregulation of the immune response, leading to the production of antibodies that can cause inflammation and damage to body tissues. IGHV3-30-2 has been shown to play a role in the regulation of the production and function of autoantibodies, which are antibodies that are produced by the immune system in response to the presence of a particular antigen.

IGHV3-30-2 has also been shown to be involved in the regulation of the production and function of hematopoietic stem cells, which are responsible for the production of all of the different blood cells in the body. These stem cells have the potential to develop into any type of blood cell, including red blood cells, white blood cells, and platelets. IGHV3-30-2 has been shown to play a role in the regulation of the production and function of hematopoietic stem cells, which may have implications for the treatment of anemia and other disorders that affect blood cell production.

In addition to its potential as a drug target or biomarker, IGHV3-30-2 has also been shown to have potential clinical applications in a variety of other areas. For example, IGHV3-30-2 has been shown to be involved in the regulation of the production and function of natural killer cells, which may have implications for the treatment of cancer. In addition, IGHV3-30-2 has been shown to be involved in the regulation of the production and function of autoantibodies, which may be involved in the development of autoimmune disorders.

Overall, IGHV3-30-2 is a protein that has been shown to be involved in a variety of biological processes that are important for human health. As a potential drug target or biomarker, IGHV3-30-2 has the potential to contribute to the treatment of a wide range of diseases. Further research is needed to fully understand the role of IGHV3-30-2 in these processes and to develop effective treatments.

Protein Name: Immunoglobulin Heavy Variable 3-30-2 (pseudogene)

The "IGHV3-30-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-30-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets